Free Trial

MEI Pharma Q2 2025 Earnings Report

MEI Pharma logo
$2.13 -0.02 (-0.93%)
As of 04:00 PM Eastern

MEI Pharma EPS Results

Actual EPS
-$0.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

MEI Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MEI Pharma Announcement Details

Quarter
Q2 2025
Time
After Market Closes

Conference Call Resources

Remove Ads

MEI Pharma Earnings Headlines

MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
MEI Pharma Registered Shs
MEI Pharma (NASDAQ:MEIP) Stock, Option Chain
See More MEI Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MEI Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MEI Pharma and other key companies, straight to your email.

About MEI Pharma

MEI Pharma (NASDAQ:MEIP), a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

View MEI Pharma Profile

More Earnings Resources from MarketBeat